Imugene PRRS vaccine succeeds in pig trial
Preliminary results from Imugene's recently completed
pig trial in the US have been released. The results show that new modified PRRS
vaccine Imugene's [ASX:IMU] provides a very high degree of protection against
the PRRS disease when two doses are administered either orally or by
Porcine Reproductive and Respiratory
is caused by a viral infection. The major clinical signs are the result of areas
of diseased lung (consolidation). To evaluate the severity of an infection,
standardised lung lesion scores are generated by scoring the diseased areas in
each of the 7 lung lobes from each pig and then generating an average.
The lower the average lung lesion score the better, as this indicates a
lower level of disease. In addition, clinical illness slows weight gain during
and after infection. An effective vaccine should result in less clinical illness
and therefore better weight gains following infection.
challenge with the live PRRS virus, vaccinated pigs had much lower lung lesion
scores and better weight gains over the 14 day post-challenge period compared to
the unvaccinated control pigs.
The trials were undertaken at a
specialist trial facility in the US. A full trial report including statistical
analysis is being prepared and is expected in the next 4-6 weeks. Imugene will
now use these results in discussions with major international animal health
companies with a view to possible licensing agreements.
Subscribe here to
the Pig Progress newsletter
To comment, login here
Or register to be able to comment.